Genomed

Genomed P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Genomed (GEN.WA) as of Oct 27, 2026 is 16.17. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -1,263.30 — a change of -101.28% (higher).

P/FCF

16.17

YoY

-101.28%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Genomed is 2025 16.17 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Genomed was 2024 -1,263.30 . It decreases by -101.28% higher compared to the previous year.

The Genomed P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-25.91 PLN
Jan 1, 2019
194.35 PLN
Jan 1, 2020
38.58 PLN
Jan 1, 2021
20.10 PLN
Jan 1, 2022
-56.60 PLN
Jan 1, 2023
19.33 PLN
Jan 1, 2024
-1,263.30 PLN
Jan 1, 2025
16.17 PLN
The Genomed P/FCF history
YEARP/FCFYoY
16.17-101.28%
-1,263.30-6,634.75%
19.33-134.16%
-56.60-381.55%
20.10-47.90%
38.58-80.15%
194.35-850.17%
-25.91-56.76%
-59.91-114.97%
400.11-2,562.68%
-16.25—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genomed Stock analysis

What does Genomed do? Genomed SA generates revenue through molecular diagnostics services based on DNA sequencing, particularly Next Generation Sequencing (NGS). The company offers gene mutation analysis for over 150 congenital diseases including infertility, cancer predisposition, cystic fibrosis, Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy, and obesity. Their primary clients are healthcare providers and research institutions seeking personalized medicine solutions and genomic technology integration. Genomed SA also provides DNA sequencing, analysis, and synthesis services for the biotechnological market, targeting academic and industrial research sectors. The company's business model focuses on developing advanced diagnostic tools for medical applications, with a strong emphasis on NGS technology. Their service portfolio includes specialized genetic testing for congenital conditions and research-oriented DNA services. By concentrating on personalized medicine and gene treatment clinics, Genomed SA positions itself as a provider of specialized genomic solutions for both clinical and research markets. Genomed SA's revenue streams are derived from diagnostic testing services for congenital diseases and biotechnological DNA services. The company serves healthcare facilities requiring genetic analysis for patient care and research organizations needing genomic data for scientific advancement. Their offerings target medical professionals and biotechnology companies seeking to implement genomic technology in their operations. Genomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomed stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Genomed is 16.17 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Genomed changed from -1,263.30 to 16.17, representing a -101.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Genomed since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Genomed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Genomed

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Genomed